Does CT colonography have a role for population-based colorectal cancer screening?

Abstract

Colorectal cancer (CRC) is the second most common cancer and second most common cause of cancer-related deaths in Europe. CRC screening has been proven to reduce disease-specific mortality and several European countries employ national screening programmes. These almost exclusively rely on stool tests, with endoscopy used as an adjunct in some countries. Computed tomographic colonography (CTC) is a potential screening test, with an estimated sensitivity of 88 % for advanced neoplasia ≤10 mm. Recent randomised studies have shown that CTC and colonoscopy have similar yields of advanced neoplasia per screened invitee, indicating that CTC is potentially viable as a primary screening test. However, the evidence is not fully elaborated. It is unclear whether CTC screening is cost-effective and the impact of extracolonic findings, both medical and economic, remains unknown. Furthermore, the effect of CTC screening on CRC-related mortality is unknown, as it is also unknown for colonoscopy. It is plausible that both techniques could lead to decreased mortality, as for sigmoidoscopy and gFOBT. Although radiation exposure is a drawback, this disadvantage may be over-emphasised. In conclusion, the detection characteristics and acceptability of CTC suggest it is a viable screening investigation. Implementation will depend on detection of extracolonic disease and health-economic impact. Key Points ̇ Meta-analysis of CTcolonographic screening showed high sensitivity for advanced neoplasia ≤10mm. ̇ CTC, colonoscopy and sigmoidoscopy screening all have similar yields for advanced neoplasia. ̇ Good quality information regarding the cost-effectiveness of CTC screening is lacking. ̇ There is little good quality data regarding the impact of extracolonic findings. ̇ CTC triage is not clinically effective in first round gFOBT/ FIT positives. © European Society of Radiology 2012.